279 East Grand Ave
South San Francisco
About DNA Script
DNA Script is a leading company in manufacturing de novo synthetic nucleic acids using a proprietary enzymatic technology. DNA Script's approach leverages nature's billions of years of evolution in synthesizing DNA to set a new standard for how nucleic acids are made and accelerate the adoption of synthetic biology across diverse disciplines such as biopharma, sustainable chemistry and data storage. DNA Script’s first product will be a DNA printer. On course to hit the shelves in 2021, this benchtop instrument will enable researchers to target and program specific areas of the genome.
To date, DNA Script has raised over $100M of financing, mostly through leading investors such Casdin, Agilent, Danaher, LSP, Bpifrance, Illumina Ventures, Merck Ventures, Sofinnova Partners, Kurma Partners, Idinvest.
DNA Script has its research facility headquartered in Paris, France, and is in the process of expanding its commercial and development teams in South San Francisco.
We’re science-driven thinkers, makers, dreamers and do-ers. Our goal is to develop technology to accelerate advances in life sciences and health.
DNA Script is now moving to a new stage of development, i.e. commercialization. That’s why we are looking for new talents in different fields: R&D, manufacturing and supply chain, sales and marketing, industrial and IT engineering, etc.
If you are passionate about life sciences and their projects, curious, motivated, proactive and want to invest in a company with an innovative project, do not hesitate to send us your application!
Join DNA Script means :
- Participate and bring to life a project that makes sense and will have a real impact on future generations
- Be part of a strong scientific and technical environment: a technology that pushes the limits of what is today possible in the world of DNA synthesis. Collaborations with MIT, Harvard etc.
- A scalable position: you will benefit from training, work on transversal projects, etc.
- Discover different cultures because at DNA Script we come from all over the world.
- Friday breakfast, afterworks and teambuildings frequently
- A management with values Excellence, transparency and kindness, where the well-being is not just a promise!
French office: 67 avenue de Fontainebleau, 94 270 Le Kremlin-Bicêtre
Discover Dna Script with Sylvain, COO & cofounder
13 articles with DNA Script
DNA Script Advances Evaluation Program for the SYNTAX System, the First Benchtop DNA Printer Powered By Enzymatic Synthesis
DNA Script, a leading pioneer in enabling enzymatic DNA synthesis on demand, announced the third and final phase of its evaluation program for the SYNTAX System, the world's first benchtop printer powered by Enzymatic DNA Synthesis technology.
Company will receive up to $5 Million in grant funds from DARPA as part of the agency's Nucleic Acids On-Demand World-Wide Program to plan for and prevent the next viral pandemic
GE Research selected DNA Script to join a collaboration working on a rapid response, mobile platform to develop on-demand production of nucleic acid-based vaccines and therapies related to biological threats.
DNA Script Signs Innovation Development Contract With French Defence Innovation Agency to Enable On-Demand Diagnostics Against Emerging Biothreats
Company will receive $1.6 Million to develop a qPCR probe manufacturing platform to enable the fast detection of highly pathogenic viruses and bacteria
7/30/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
Casdin Capital leads the $50M extension; funding will support commercial launch of SYNTAX™ the world’s first enzymatic DNA printer.
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
Oversubscribed round led by LSP will fund accelerated product development and commercial operations in the U.S.
DNA Script Announces World’s First Enzymatic Synthesis of a High-Purity 200-Nucleotide Strand of DNA
Dr. Geoff Smith and Dr. Robert Nicol join the newly created Advisory Board as the company gears up to commercialize its trailblazing enzymatic DNA synthesis technology.
Company creates U.S. subsidiary and adds Dr. Jeffrey Jeddeloh, Dr. Stephen Macevicz and Dr. Christine Peponnet.
DNA Script Awarded $2.7M in Innovation Grants From Bpifrance — Total Financing Raised to Date Is $27M
This new grant will be dedicated to the development of the company’s platform for biomanufacturing long DNA constructs for cell and gene therapy applications.
DNA Script and Dynamic Combinatorial Chemistry Enter Exclusive Partnership to Enable Enzymatically Synthesized DNA
DNA Script and Dynamic Combinatorial Chemistry (DCC) announced today an exclusive licensing agreement that will expand the use by DNA Script of a novel DNA building block, commercialized by DCC, to synthesize high purity synthetic DNA and other nucleic acids.